### Form 4

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. **Title and Address of Reporting Person**
   DesJardin Michael A.
   C/O HORIZON THERAPEUTICS PLC,
   CONNAUGHT HOUSE 1ST FL, 1 BURLINGTON RD
   DUBLIN L2 4

2. **Issuer Name and Ticker or Trading Symbol**
   Horizon Therapeutics Public Ltd Co [HZNP]

3. **Date of Earliest Transaction (Month/Day/Year)**
   05/05/2020

4. **Date of Amendment, Date of Original Filed (Month/Day/Year)**
   05/07/2020

5. **Relationship of Reporting Person(s) to Issuer**
   Director
   EVP, Technical Operations

6. **Individual or Joint/Group Filing (Check Applicable Line)**
   X Form filed by One Reporting Person
   Form filed by More than One Reporting Person

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| Title of Security (Instr. 3) | Transaction Date (Month/Day/Year) | Deemed Execution Date, if any (Month/Day/Year) | Transaction Code (Instr. 8) | Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | Number of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | Amount or Number of Securities
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Ordinary Shares</td>
<td>05/05/2020</td>
<td></td>
<td>8</td>
<td>A</td>
<td>8,980</td>
<td>$38</td>
</tr>
<tr>
<td>Ordinary Shares</td>
<td>05/06/2020</td>
<td></td>
<td>8</td>
<td>A</td>
<td>8,979</td>
<td>$41.19</td>
</tr>
<tr>
<td>Ordinary Shares</td>
<td>05/07/2020</td>
<td></td>
<td>M</td>
<td>A</td>
<td>23,159</td>
<td>$14.93</td>
</tr>
</tbody>
</table>

#### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th>Title of Derivative Security (Instr. 3)</th>
<th>Conversion or Exercise Price of Derivative Security</th>
<th>Transaction Date (Month/Day/Year)</th>
<th>Deemed Execution Date, if any (Month/Day/Year)</th>
<th>Transaction Code (Instr. 8)</th>
<th>Number of Derivative Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)</th>
<th>Date Exercisable</th>
<th>Expiration Date</th>
<th>Title</th>
<th>Amount or Number of Shares</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stock Option (Right to Buy)</td>
<td>$14.93</td>
<td>05/07/2020</td>
<td></td>
<td>M</td>
<td>23,159</td>
<td>(2)</td>
<td>12/14/2026</td>
<td>Ordinary Shares</td>
<td>23,159</td>
</tr>
</tbody>
</table>

**Explanation of Responses:**

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 4, 2020.
2. 25% of the shares subject to the option vested and became exercisable on the first anniversary of the date of grant (December 15, 2016), and the remaining shares vest in 36 equal monthly installments thereafter.

**Remarks:**

\[/\] Miles W. McHugh

**Signature of Reporting Person**

**Date**

05/07/2020

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).


Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.